| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $81,252,067 ) (Continued on the next page) |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG082681 | Role of p21 positive senescent cells in radiation-induced skeletal injury and repair | 000 | 3 | NIH | 4/9/2025 | $363,150 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK136731 | Quantitative characterization of the liver-pancreas axis in diabetes via multiparametric magnetic resonance elastography | 000 | 3 | NIH | 5/1/2025 | $399,749 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG081955 | Validation of the Mayo Test Drive Screening Battery Composite and Stricker Learning Span for Early Detection and Monitoring of Cognitive Decline in Preclinical and Prodromal Alzheimer’s Disease | 000 | 2 | NIH | 11/18/2024 | $1,347,320 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL166187 | Fibrogenic activation and memory in the lung mesenchyme | 000 | 3 | NIH | 12/11/2024 | $536,436 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA262613 | Intravenous VSV virotherapy in lymphoma | 000 | 3 | NIH | 4/1/2025 | $557,778 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL151379 | Evaluating the natural evolution of myocardial stiffness in aging, sex differences, and through menopause transition in women, using a free-breathing magnetic resonance elastography approach | 000 | 3 | NIH | 1/21/2025 | $525,686 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK129205 | Renal Microvessel Imaging for Characterization of Chronic Kidney Disease | 000 | 3 | NIH | 12/31/2024 | $475,882 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI089714 | Inflammatory cascades disrupt Treg function through epigenetic mechanisms | 000 | 15 | NIH | 12/20/2024 | $464,261 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23HL164901 | Peripheral Limitations in Pulmonary Hypertension and Effects of Muscle Training | 000 | 3 | NIH | 2/22/2025 | $167,741 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA275870 | Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity | 001 | 3 | NIH | 2/14/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA275870 | Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity | 000 | 3 | NIH | 1/7/2025 | $559,858 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK130854 | Role of SLCO3A1 in macrophage metabolite sensing and IBD | 000 | 3 | NIH | 12/12/2024 | $314,820 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK057061 | Calcium Dynamics in Interstitial Cells of Cajal | 002 | 24 | NIH | 12/11/2024 | $524,544 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS126227 | Seronegative Autoimmune Encephalopathies: Biomarker Discovery, Validation & Deep Phenotyping | 000 | 4 | NIH | 1/17/2025 | $357,750 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI184360 | Mechanisms of genetic variants in TH2 autoimmunity | 000 | 2 | NIH | 4/21/2025 | $606,229 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA271503 | Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma | 001 | 3 | NIH | 2/14/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA271503 | Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma | 000 | 3 | NIH | 1/28/2025 | $485,587 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK133194 | Exercise Response in Humans with Obesity | 000 | 3 | NIH | 4/25/2025 | $697,543 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL162828 | Pulmonary Hypertension in Left Heart Disease | 000 | 3 | NIH | 4/24/2025 | $710,655 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK136511 | Pathobiology of liver fibrosis | 000 | 3 | NIH | 4/29/2025 | $355,080 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB035553 | Improving the dose efficiency of photon counting CT | 000 | 2 | NIH | 4/25/2025 | $362,179 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA273027 | Role of MALT1 in regulating the breast cancer immune microenvironment | 002 | 3 | NIH | 11/29/2024 | $485,171 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK127978 | Hepatic Steatosis Quantification with Ultrasound | 000 | 4 | NIH | 4/18/2025 | $499,499 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31NS141217 | Identifying molecular mechanisms contributing to disease etiology and the neurological symptoms associated with pediatric DPD deficiency | 000 | 1 | NIH | 1/28/2025 | $48,974 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AR077538 | The impact of age-related changes in osteoclast function on the skeleton | 000 | 5 | NIH | 4/16/2025 | $256,399 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL166238 | Electrochemical Catheter for Prevention of Central Line-Associated Bloodstream Infection | 000 | 3 | NIH | 2/19/2025 | $382,186 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA272496 | Targeting PLK1 in RAS mutant chronic myelomonocytic leukemia | 000 | 3 | NIH | 3/14/2025 | $384,419 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01AI179609 | Mitochondrial Malfunction in T Cell Aging and Tissue Inflammation | 000 | 2 | NIH | 2/12/2025 | $563,609 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG081584 | Biophysically inspired mechanical biomarkers of normal pressure hydrocephalus | 000 | 2 | NIH | 3/20/2025 | $363,150 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK099160 | Molecular dissection of the ciliary gate | 002 | 11 | NIH | 12/11/2024 | $375,861 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL171056 | INTEGRATION OF MECHANICAL AND MOLECULAR CUES DURING DISTAL LUNG DEVELOPMENT | 000 | 2 | NIH | 12/23/2024 | $532,264 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076636 | Advancing MR elastography to map mechanical signatures of key AD/ADRD processes | 000 | 3 | NIH | 11/28/2024 | $397,775 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA248147 | Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer | 001 | 5 | NIH | 2/14/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA248147 | Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer | 000 | 5 | NIH | 1/3/2025 | $564,664 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01GM144351 | Methods for microbiome compositional data | 000 | 4 | NIH | 12/20/2024 | $295,083 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA132878 | Post-translational Modifications in DNA Damage Response: a Structural Perspective | 001 | 12 | NIH | 2/13/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA132878 | Post-translational Modifications in DNA Damage Response: a Structural Perspective | 000 | 12 | NIH | 1/13/2025 | $363,150 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB033008 | Development of an ultrasound detectable, migration-resistant biopsy marker for improving care in patients with breast cancer | 000 | 3 | NIH | 12/5/2024 | $557,828 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK059597 | Investigation of common disease mechanisms in nonsyndromic and syndromic PKD | 000 | 24 | NIH | 12/12/2024 | $529,467 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AI178147 | Role of the CX3CL1-CX3CR1 signaling axis in IPMN | 000 | 2 | NIH | 12/18/2024 | $195,698 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA286349 | Characterization and treatment of a novel model of radiation optic neuropathy using the tree shrew | 000 | 2 | NIH | 4/4/2025 | $48,601 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA276005 | Aak1 to increase infiltration of adoptively transferred cells into solid tumors | 000 | 3 | NIH | 1/27/2025 | $411,873 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK129240 | Role of mitochondrial microRNAs (mitomiRs) in endogenous renal repair | 000 | 3 | NIH | 11/28/2024 | $411,653 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA269384 | Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors. | 000 | 3 | NIH | 11/25/2024 | $327,341 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS112153 | Flortaucipir PET and histopathology in frontotemporal lobar degeneration and Alzheimer’s disease | 000 | 3 | NIH | 2/13/2025 | $363,150 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21EB034346 | Next generation of delivery platform for Prime editors based on an RNA vector for Sickle cell disease: the “all-in-one” vector | 000 | 2 | NIH | 4/2/2025 | $181,575 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA266344 | Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines | 001 | 4 | NIH | 2/12/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA266344 | Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines | 000 | 4 | NIH | 1/23/2025 | $554,542 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL160761 | Mechanisms of Clinical and Hemodynamic Response to Pulmonary Vasodilator Therapy in Fontan physiology | 000 | 4 | NIH | 1/23/2025 | $571,997 |
|
